



15W

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:
Date: June 7, 2004 Name: Magdalena O. Cilella, Ph.D. Signature: *Magdalena O. Cilella*

BRINKS
HOFER
GILSON
& LIONE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Wei et al.

Appln. No.: 10/630,180

Filed: July 30, 2003

For: METHOD FOR MULTIPLE CHEMOKINE
RECEPTOR SCREENING FOR
ANTAGONISTS USING RAM ASSAY

Attorney Docket No: 10709/47

Examiner: Not yet assigned

Art Unit: 1645

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Attached is/are:

- First Supplemental Information Disclosure Statement (in duplicate).
- PTO Form 1449 with copy of cited reference B1.
- Return Receipt Postcard.

Fee calculation:

- No additional fee is required.
- An extension fee in an amount of \$ _____ for a _____-month extension of time under 37 C.F.R. § 1.136(a).
- A petition or processing fee in an amount of \$ _____ under 37 C.F.R. § 1.17(_____.)
- An additional filing fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Small Entity		or	Not a Small Entity	
					Rate	Add'l Fee		Rate	Add'l Fee
Total		Minus			x \$9=			x \$18=	
Indep.		Minus			x 43=			x \$86=	
First Presentation of Multiple Dep. Claim					+\$145=			+\$290=	
					Total	\$		Total	\$

Fee payment:

- A check in the amount of \$ _____ to cover the above-identified fee(s) is enclosed.
- Please charge Deposit Account No. 23-1925 in the amount of \$ _____. A copy of this Transmittal is enclosed for this purpose.
- Payment by credit card in the amount of \$ _____ (Form PTO-2038 is attached).

The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Date

6/7/04

Respectfully submitted,

Magdalena Cilella

Magdalena O. Cilella, Ph.D.

Limited Recognition Certificate Enclosed

Agent of Attorney for Applicants



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450, on

June 7, 2004

Date of Deposit

Magdalena O. Cilella, Ph.D.

Name of Applicant, Assignee or
Registered Representative

Signature

June 7, 2004

Date of Signature

Our Case No.: 10709/47

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wei et al.

Serial No.: 10/630,180

Filing Date: July 30, 2003

For: METHOD FOR MULTIPLE
CHEMOKINE RECEPTOR
SCREENING FOR ANTAGONISTS
USING RAM ASSAY

Examiner:

Group Art Unit No.: 1645

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this First Supplemental Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the

Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

Other Art:

Hesselgesser et al., J Biol Chem 1998, 273(25):15687-92

In accordance with 37 C.F.R. § 1.97(g),(h), this First Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This First Supplemental Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this First Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

This application is a continuation-in-part application of U.S. Serial No. 10/154,399, filed May 22, 2002 and is relied upon for an earlier filing dated under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of documents not previously cited and submitted to the Patent and Trademark Office in the prior application Serial No. 10/154,399 are enclosed for the convenience of the Examiner.

Applicant(s) respectfully request that the listed documents be made of record in
the present case.

Respectfully submitted,

6/7/04

Magdalena Cilella

Magdalena O. Cilella, Ph.D.
Limited Recognition Certificate Enclosed
Agent of Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200



FORM PTO-1449 U.S. PATENT & TRADEMARK OFFICE	SERIAL NO. 10/630,180	CASE NO. 10709/47
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		FILING DATE July 30, 2003
(use several sheets if necessary)		APPLICANTS: Wei, et al.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

REFERENCE DESIGNATION		CROSS-REFERENCED DOCUMENTS			CLASS/ SUBCLASS	FILING DATE
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME			

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
B1	Hesselgesser et al., J Biol Chem 1998, 273(25):15687-92	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next
communication to applicant.